Penicillamine-induced pemphigus erythematosus.
Pemphigus erythematosus occurred in a patient with rheumatoid arthritis who was treated with D-penicillamine. The skin lesions appeared 4 months after the onset of D-penicillamine treatment and persisted 14 years after cessation of this drug. Topical betamethasone dipropionate applications resulted in complete regression of the cutaneous lesions.
Department of Dermatology, Akademisch Ziekenhuis Vrije Universiteit Brussels, Belgium.
M J
MJ
Willemsen
A L
AL
De Coninck
L E
LE
De Raeve
D I
DI
Roseeuw
D000279:Administration, Cutaneous; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001623:Betamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005455:Fluorescent Antibody Technique; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced* / Q000276:immunology; D010396:Penicillamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000031:analogs & derivatives; D012867:Skin / Q000276:immunology / Q000473:pathology
D007075:Immunoglobulin M; C036069:penicillamine disulfide; D001623:Betamethasone; D010396:Penicillamine